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urement of hope and 639 abstracts on the measurement of psychological func-
tion in cancer were screened to identify publications focusing on the development 
of psychological instruments. In some cases, an article describing a promising 
instrument was selected and then used to identify the original validation study 
which was then substituted as the article selected for full text review. 16 measures 
with a hope focus or hope-specific items were identified for further review and 9 
measures of positive psychological constructs developed for use in the context of 
cancer were identified for further review. ConClusions: Positive psychological 
constructs factor into cancer treatment and symptom remission. Measurement of 
these domains is an important component of treatment selection and outcomes 
assessment. However, reliable and valid assessment of hope and related constructs 
depends on the availability of psychometrically sound instruments developed for 
this context of use. The present study demonstrates that while much work has 
been done in research settings to develop such measures, there is still a need for 
further refinement and development of these tools so that they are fit for use in a 
regulated research context.
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objeCtives: Overall aim of this study is to evaluate acceptability and usability of 
the Quality of Life-Portal (QOL-Portal), developed for breast cancer patients. The 
portal is designed for assessing information needs and patient’s QOL and enhanc-
ing patient education as well as health literacy. Methods: Software development 
has been done in close collaboration with a multidisciplinary group of healthcare 
professionals following an Extreme Programming approach. This means that soft-
ware development was based on an stepwise process that included the evaluation 
of individual components of the portal by healthcare professionals and subsequent 
adaptation in accordance with the provided feedback. Currently, we are conduct-
ing semi-structured interviews in breast cancer patients to collect information 
on acceptability and usability of the QOL-Portal. The main evaluation criteria are 
divided into usability (e.g. possible problems with web-access, user-friendliness and 
satisfaction) and content (e.g. understandability of information and of graphical 
questionnaire presentation). Results: Software development has been completed 
and resulted in an online QOL portal for breast cancer patients. Based on feedback 
from healthcare professionals we developed several components for the portal: an 
information module to enhance patients’ condition and treatment related knowl-
edge, health literacy, a symptom monitoring tool based on the EORTC questionnaires 
(allowing assessments in the hospital and at home), and a basic set of self-help 
interventions. In addition, the portal provides graphical feedback on the QOL results 
to patients themselves. Preliminary results from the ongoing patient interviews will 
be presented at the conference. ConClusions: QOL-Portals are gaining importance 
as they allow routine symptom assessment and provide important information to 
patients and medical alike. We have developed key components for the portal which 
undergo further adaption and improvement based on feedback from healthcare 
professionals and patients. In a next step, we will evaluate the impact of the portal 
on patients’ QOL.
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objeCtives: Oral chemotherapy was developed to reduce in-patient stays while 
providing the same level of efficacy and safety. This study assessed the health-
related quality of life (HRQoL) of patients treated with oral vinorelbine for metastatic 
NSCLC and their caregivers. Methods: This longitudinal survey assesses 2 visits 
documenting the second and third chemotherapy cycles. Patients had metastatic 
NSCLC and received oral vinorelbine (day 1 and 8 of 3-week cycles) and carboplatin 
(day 1). Baseline measures included demographics, anamnesis, co-morbidities and 
current treatment. SF-12 was reported at the end of each cycle, on the patients 
and interestingly on the caregivers. Results: Three Danish centers included 45 
patients: median age: 66.9 y.o., 53.3% were male. Performance status (ECOG) was 
0: 33.3%; 1: 51.1%; 2+: 15.6%. Main reason for choosing oral vinorelbine was con-
venience. Caregivers, mainly spouses (76.7%), were 57.8 y.o. No major change on 
SF-12 scores was reported between cycle 2 and 3. Physical summary scores (PCS) of 
patients (37.0-38.6, respectively cycle 2 and 3) were lower than those of caregivers 
(52.9-53.4) and general population (44). Mental summary scores (MCS) of patients 
(47.7-44.2) and caregivers (46.2-44.6) were much lower than those one of a popula-
tion of same age (patient: 52; caregiver: 51). The most affected patient scores were 
physical functioning (40.4), role physical (40.1), vitality (37.2). Social functioning (SF) 
was similarly high in patients and caregivers (76.9 vs. 78.9, patient vs. caregiver) 
while mental health of both patients and caregivers were lower (66.7 vs. 65.5) than 
SF. ConClusions: Metastatic NSCLC deeply affects patients’ HRQoL as measured 
by a generic instrument, both on MCS and PCS. Caregivers’ HRQoL is also affected, 
mainly on MCS. Patients receiving oral vinorelbine plus carboplatin and their car-
egivers maintain a good level of social functioning.
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with the use of a single approach (such as a single centre), (iii) the health state of 
the participant, and (iv) the burden on site staff affecting recruitment. The protocol 
addresses issue (i) by describing effectiveness in terms of time to need for new 
treatment rather than disease progression as well as cognitive debriefing; issues 
ii & iv using a broad spectrum of recruitment methods; (iii) minimising patient 
burden. ConClusions: The development of this protocol has been informed by 
lessons learnt from previous research. An analysis of the issues identified as limita-
tions in previous studies in collecting patient preference data allows improvements 
in protocol design.
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objeCtives: Patient-reported outcomes (PRO) provide a more comprehensive pic-
ture of patients’ quality of life than do mere physicians’ ratings. Electronic data 
collection of PRO offers several advantages and allows assessments at patients’ 
homes as well. This study reports on patients’ internet use, their attitudes towards 
electronic and web-based PRO assessment (clinic-ePRO and home-ePRO) and the 
feasibility of these two assessment modes. Methods: At the Medical University 
of Innsbruck and Kufstein County Hospital, cancer patients who participated in 
clinic-ePRO/home-ePRO were asked to complete a comprehensive evaluation form 
on their internet usage, attitudes towards and the feasibility of routine clinic-
ePRO/home-ePRO with the Computer-based Health Evaluation System (CHES) 
software. Results: In total, 158 patients completed the evaluation form. Most 
patients expressed willingness to complete routine clinic-ePRO (92.3%)/home-
ePRO (70%) assessments in the future and to discuss such data with attending 
physicians (82.2%). The CHES software for home-ePRO was preferred over phone 
interviews by 95.7% of patients and 72.7% experienced it as easy to use. Only a few 
minor suggestions for improvement were made. Overall satisfaction with home-
ePRO was high with an average rating of 9.1 points (range 5-10 points). However, 
there became an age bias apparent, as participating patients were approximately 
ten years younger than those refusing clinic-ePRO/home-ePRO. ConClusions: 
The use of clinic-ePRO/home-ePRO was in general shown to be feasible and well 
accepted. However, to be more inclusive in the implementation of clinic-ePRO/
home-ePRO, educational programs concerning their particular benefit in oncology 
practice potentially could enhance patients’ attitudes towards, and consequently 
their acceptance of and compliance with electronic PRO assessments.
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objeCtives: To investigate the effects of adverse events on quality of life (QOL) scores 
during adjuvant chemotherapy for breast cancer patients. Methods: We analyzed 
the QOL scores assessed by EQ-5D and the worst grades of adverse events assessed 
by the National Cancer Institute - Common Toxicity Criteria(NCI-CTC) Version 2.0 
collected from a national multicenter phase III randomized clinical trial: National 
Surgical Adjuvant Study of Breast Cancer-02 (N-SAS BC 02), which compared two 
types of taxane-containing chemotherapy, as an approved sub analysis numbered 
CSP-HOR22. A linear regression model was constructed with change in EQ-5D score 
as an objective variable, calculated as the worst scores minus the baseline (before 
chemotherapy) scores, and the incidences of adverse events as independent vari-
ables, set as binary variables regardless of grade. Results: From 300 participants, 
250 complete series of data of EQ-5D scores and adverse events were extracted. The 
average baseline EQ-5D score was 0.798. The average of worst EQ-5D scores for each 
participant during chemotherapy was 0.720 and the average change in EQ-5D score 
was -0.078, with a range of -0.619 to +0.464. Although QOL deteriorated in 140 patients, 
it improved in 54 patients. Seventeen adverse events were selected as independent 
variables excluding rare ones. The following three coefficients of the regression model 
were significant; edema: -0.056 (p= 0.03), phlebitis: 0.068 (p= 0.01), and sensory nerve 
disturbance: -0.084 (p< 0.01), and these results are equivalent to simple linear regres-
sion models for each factor. ConClusions: Cases of QOL improvement events may 
have reduced the model’s descriptive power and caused a positive coefficient value. 
Since patients treated with taxane-containing chemotherapy often suffer sensory 
nerve disturbance as well as edema for a longer period, even after the termination 
of chemotherapy, clinicians should provide selective care to avoid deterioration of 
patients’ QOL.
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objeCtives: To understand the ways in which hope and related constructs are 
applied and measured in the context of healthcare, especially in patients with 
cancer. Targeted literature reviews were conducted in two areas: (1) Psychological 
assessments measuring hope, and (2) Measures of psychological function in 
cancer-related care, including well-being and other positive psychological con-
structs. Methods: To better understand the scope of psychological assessments 
developed and currently in use to measure hope and related positive psychological 
constructs in the context of healthcare, a targeted review of the published literature 
was undertaken. MEDLINE and PsychINFO database searches were conducted for 
publications in English in the past 5 years. Results: 876 abstracts on the meas-
A474  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
PCN248
Cost-utility ANAlysis of eNzAlutAmiDe for PAtieNts WitH 
CHemotHerAPy-NAïve metAstAtiC CAstrAtioN-resistANt ProstAte 
CANCer (mCrPC) After fAilure of ANDrogeN DePrivAtioN tHerAPy (ADt)
Vicente C1, Loblaw A2, North S3, Kassouf W4, Naidoo S5, Husein F6, Nakhaipour HR6
1PIVINA Consulting Inc., Mississauga, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 
3University of Alberta, Edmonton, AB, Canada, 4McGill University Health Centre, Montreal, QC, 
Canada, 5Astellas, Chertsey, UK, 6Astellas, Markham, ON, Canada
objeCtives: Enzalutamide prolonged overall survival and radiographic progres-
sion-free survival (rPFS), delayed initiation of cytotoxic chemotherapy and main-
tained quality of life in patients with chemotherapy-naïve mCRPC after failure of 
ADT (PREVAIL; Beer et al 2014). The cost-effectiveness of enzalutamide, compared 
with abiraterone plus prednisone (ABI+P) for patients with chemotherapy-naïve 
mCRPC, was evaluated from the perspective of the Canadian Ministries of Health 
(MoH). Methods: A Markov model was developed to capture time spent by patients 
in various health states: stable, progression and death. Results were reported as 
incremental costs per additional quality-adjusted life year (QALY) gained over a 
10-year period. Transition probabilities were derived from patient-level data from 
PREVAIL and a network meta-analysis (NMA) of available trials. Base case analysis 
focused on direct medical costs from the Canadian MoH perspective. Cost data was 
obtained from a variety of Canadian sources, valued in 2015 Canadian dollars. A 
5% discount rate was applied to costs and outcomes. Multiple sensitivity analyses 
were performed. Results: NMA results suggested no difference between enzalu-
tamide and ABI+P for overall survival, but indicated that enzalutamide is superior 
to ABI+P for rPFS (hazard ratio 0.35; credible interval 0.27, 046). The improvement 
in rPFS translated into a longer mean duration of stable disease with enzalutamide 
(36.7 months) than with ABI+P (16.4 months), and greater total QALYs (enzaluta-
mide 2.65; ABI+P 2.23). From the Canadian MoH perspective, enzalutamide had an 
incremental cost-effectiveness ratio (ICER) of $92,690 per additional QALY gained 
versus ABI+P. The ICER was robust over a wide range of sensitivity analyses. In the 
probabilistic sensitivity analysis, the mean ICER was $110,036 per QALY gained 
versus ABI+P, with > 60% of iterations falling below a willingness-to-pay threshold 
of $100,000 per QALY gained. ConClusions: Enzalutamide is considered a cost-
effective treatment option compared to ABI+P in patients with chemotherapy-naïve 
mCRPC after failure of ADT.
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eAsterN CooPerAtive oNCology grouP (eCog) PerformANCe stAtus (Ps) 
is AN iNDePeNDeNt PreDiCtor of HrQol iN uNreseCtAble or metAstAtiC 
melANomA
Harrison JP, Kim H
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objeCtives: In analysis of health state utilities derived from a nivolumab phase 
III clinical trial a statistically significant difference in baseline utilities was noted 
between nivolumab (NIVO) and dacarbazine (DTIC) treatment arms. The aim of 
this study was to analyse and assess possible drivers of this difference in mean 
baseline utility. Methods: Patient demographics and baseline disease charac-
teristics were compared between treatment arms to identify any variables which 
may be responsible for the observed differences in baseline utilities. All identi-
fied variables were included in a generalised linear model and tested for signifi-
cance differences in a stepwise manner to determine the final predictive utility 
model. Results: Population demographics and baseline disease characteristics 
were generally well balanced between treatment arms, however patients ran-
domised to NIVO were generally of better ECOG performance status (70.5% and 
28.6% for PS 0 and 1 respectively) than those randomised to DTIC (58.2% and 
40.4%). A generalised linear regression model of utility therefore included ECOG 
performance status in addition standard variables age, sex, weight, smoking his-
tory and metastatic stage. After stepwise elimination of non-significant variables, 
ECOG performance status was found to be a strongly significant predictor of health 
state utility (p< 0.000) as was sex (p< 0.000) and age (p= 0.006). Whilst metastatic 
stage remained in the final model specification as these were pre-defined strati-
fication factors, neither was a significant predictor of health state utility (p= 0.724, 
p= 0.493 respectively). ConClusions: ECOG performance status was found to 
be an independent predictor of health state utility in addition to age and sex. As 
such it is critical that any economic evaluation of an intervention in this patient 
population identifies any differences in performance status between intervention 
and comparator arms and seeks to establish the impact any difference may have 
on subsequent results.
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objeCtives: Bladder cancer (BC) is a disease with a high recurrence rate, neces-
sitating invasive, repeated treatments that can meaningfully impact patient health-
related quality of life (HRQoL). The goal of this review was to summarize the BC HRQoL 
literature in order to assess the impact of BC by stage and treatment. Methods: A 
systematic literature search of studies indexed in PubMed was conducted without 
language or publication year limitations. Due to the large volume of literature, subse-
quent review was refined to studies published since 2005, excluding reports utilizing 
single-use HRQoL measures without evidence of validation. Results: A review of 
~1,700 abstracts yielded a final set of 62 peer-reviewed articles (published 2005 – 2014). 
Eleven HRQoL measures (8 disease-specific, 3 generic) were identified (EORTC QLQ-
C30 and SF-36 most commonly used, in 25 and 21 studies, respectively). BC-specific 
modules such as the EORTC QLQ-NMIBC24 were included less frequently, with no 
BC-specific module in more than 8 studies. The majority of studies were of retrospec-
tive, cross-sectional study design. HRQoL impact of radical cystectomy for muscle 
Republic, 4Oncologia Medica Addarii Policlinico S.Orsola Malpighi, Bologna, Italy, 5Son Llatzer, 
Palma de Mallorca, Spain, 6Uniwersytecki Szpital Kliniczny, Worklow, Poland, 7Pierre Fabre, 
Boulogne Billancourt, France, 8STAT PROCESS, Paris, France
objeCtives: To assess the burden of illness associated with advanced breast cancer 
treated with vinorelbine oral (VinO) or IV (VinIV) from the perspective of patients 
and caregivers in 5 European countries. Methods: This was an observational, pro-
spective, international, multicentric study. Patients were included in the study at 
the beginning of their 2nd cycle of chemotherapy with vinorelbine and categorized 
in 2 groups depending on whether they are receiving VinO or VinIV. At baseline (V0) 
and at the end of the 2nd cycle of chemotherapy (V1), patients and caregivers were 
asked to complete self-administered questionnaires: SF-12, EORTC-QLQ-C30 (only 
for patients) and burden of illness. Results: At baseline, there were no major dif-
ferences in demographic and clinical characteristics between the two groups. VinIV 
was prescribed monotherapy in 56.9% and 62.5% for VinO. Patients receiving VinO 
were predominantly treated with monotherapy. In addition, as measured with SF-12, 
patients with VinO (n= 128) had, at end of cycle 1 and end of cycle 2, significantly 
more favourable outcomes in physical summary score, role physical, role emotional 
and mental health (all p< 0.05) than those treated with VinIV (n= 51). Trends for 
a better caregiver mental score and social functioning were also observed with 
VinO (cycle 1 and 2; p< 0.10). From a patient perspective, no major difference was 
reported on the burden of illness between the two groups, however, a trend for a 
better “overall impact on daily life” was observed in VinO patients. Major significant 
differences, showing a lower burden of illness with VinO, were also reported from 
caregivers (Social functioning, Overall impact on daily life). ConClusions: Oral 
vinorelbine showed some benefits over the IV form for both patients and caregivers, 
particularly in health related QoL and burden of illness.
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objeCtives: Validity and reliability are important characteristics of any instrument. 
Generic instrument are designed for use in any population; however, their validity 
and reliability in particular diseases should be verified to ensure their appropriate-
ness. In this study the authors assessed the validity and reliability of the Medical 
Outcomes Study Short Form–36 (SF-36), a generic instrument, in a population of 
patients with intradural primary spinal cord tumors (IST). Methods: The SF-36 
was administered to a cohort of patients with IST on an outpatient basis. Symptom-
related data derived from a structured interview and physical examination findings 
were used to classify cases according to the scales of McCormick and Aminoff-
Logue. Construct validity was assessed by determining whether SF-36 scores cor-
relates with the spinal cord tumors scores (McCormick score and Aminoff-Logue 
score) by using the Cuzick nonparametric test for trend. The reliability of the SF-36 
scores was assessed using Cronbach alpha. Results: One hundred patients with 
IST completed the SF-36. Construct validity was demonstrated by confirming the 
hypothesized relationship between SF-36 scales and the scales of McCormick (p _ 
0.003), Aminoff-Logue deambulation subscale (p _ 0.025), Aminoff-Logue micturi-
tion subscale (p _ 0.013), and the Aminoff-Logue defaecation subscale (p _ 0.004). 
Reliability was demonstrated for all eight SF-36 domain scales and the physical 
component and mental component summary scales, in which Cronbach alpha satis-
fied the Nunnally criterion of > 0.85. ConClusions: The SF-36 provides valid and 
reliable data on patients with IST.
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objeCtives: The aim of this analysis was to assess predictors of health-related 
quality of life over time, and to estimate utilities for patients with treatment-naïve 
advanced melanoma in the randomized CheckMate 066 trial comparing nivolumab 
with dacarbazine for use in a cost-effectiveness model (CEM). Methods: The 
EQ-5D was administered at baseline and every 6 weeks in CheckMate 066 and was 
used to generate index utility scores using the UK time trade-off (TTO) method. 
Covariates were based on a combination of prior analyses from large trial datasets, 
including patient demographic and clinical characteristics, quantitative metrics of 
fit, qualitative/clinical plausibility, and relevance to the CEM. Several longitudinal 
mixed linear models were explored using different covariate sets. Results: This 
analysis included 288 patients and 1,125 visits where the EQ-5D was administered. 
Mean baseline utility score was 0.75 for nivolumab, 0.69 for dacarbazine, and 0.72 
across both treatment arms. The final model included baseline utility (to adjust 
for imbalance between treatment arms), progression status (pre/post), days until 
death or end of follow-up (< 30 days/30+ days), and treatment arm. Parameter esti-
mates in the model were 0.603 for baseline utility (P< 0.001), −0.074 for progression 
status (P< 0.001), −0.022 for < 30 days left (P= 0.092), and −0.069 for treatment arm 
(dacarbazine vs nivolumab; P= 0.008). When implemented in the CEM, the utility 
estimate for the pre- and post-progression states were 0.802 and 0.728, respec-
tively (applying nivolumab as the treatment arm). A decrement for the month 
preceding death was applied using the estimate for < 30 days until death or end 
of follow-up (−0.022). ConClusions: These results showed that baseline utility, 
progression, < 30 days until death or end of follow-up, and treatment arm are all 
predictors of utility over time, which is consistent with prior work in melanoma. 
As data mature, these analyses will be replicated in this and other nivolumab 
trials.
